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Résumé  
 
La transplantation hépatique allogénique est le seul traitement effectif pour un grand 
nombre de maladies hépatiques, incluant l'insuffisance hépatique fulminante. 
Toutefois, le manque d'organes humains à disposition limite le nombre de 
transplantations hépatiques allogéniques et est responsable d'environ 15% de 
mortalité des patients en liste d'attente. De nouvelles sources de tissus pour la 
transplantation doivent être trouvées.  
 
La transplantation d'hépatocytes xenogénéiques plutôt que la transplantation de foie 
entier a été suggérée et pourrait constituer une source illimitée de cellules pour le 
traitement de l'insuffisance hépatique. De récentes expériences sur de petits 
animaux ont démontré que l'utilisation d'hépatocytes porcins, transplantés chez des 
rats cirrhotiques a permis la restauration partielle de fonctions métaboliques et a 
prolongé la survie des animaux receveurs. Le but de notre étude a été 
l'établissement des techniques de l'isolement, l'encapsulation, la cryo-préservation et 
la xenotransplantation d'hépatocytes porcins dans des souris avec insuffisance 
hépatique fulminante. 
 
Nous avons utilisé une méthode de perfusion de collagénase pour isoler les 
hépatocytes de porcs à partir de foies normaux. Ensuite, nous avons développé la 
méthode de micro-encapsulation utilisant l'alginate PPL comme membrane, ainsi 
que la cryo-préservation. Nous avons testé in vitro les hépatocytes avant et après 
encapsulation, avant et après cryopréservation par mesure de la sécrétion 
d'albumine par ELISA. Pour l'étude in vivo, nous avons développé un modèle 
d'insuffisance hépatique fulminante chez la souris par surdosage d'acétominophen 
suivi 15 heures plus tard par une hépatectomie de 30% conduisant à une mortalité 
reproductible d'environ 80% chez les souris non traitées. Nous avons transplanté de 
manière intra-péritonéale des hépatocytes porcins micro-encapsulés, frais ou cryo-
préservés et avons réalisé les groupes expérimentaux suivants. Groupe 1 : 
transplantation de capsules vides; Groupe 2 : transplantation d'hépatocytes porcins 
libres et frais; Groupe 3 : transplantation d'hépatocytes porcins frais encapsulés; 
Groupe 4 : transplantation d'hépatocytes cryo-préservés encapsulés. Des animaux 
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ont été euthanasiés à intervalles réguliers et nous avons réalisé l'analyse 
histologique des micro-capsules et du tissu hépatique. Nous avons obtenu les 
résultats suivants : immédiatement après isolement, la viabilité des hépatocytes 
porcins était de 76±8%. Les hépatocytes isolés frais ou cryo-préservés ont montré 
une diminution progressive de la sécrétion d'albumine durant la première semaine, 
devenant presque indétectable à J7. In vivo, la survie de souris dans les Groupes 1 
et 2 était comparable à des souris non traitées (de 18% et 25%). Dans les Groupes 
3 et 4, la transplantation d'hépatocytes frais et cryo-préservés encapsulés a permis 
une augmentation significative de la survie à 75 et 68%, respectivement (P<0,01). 
L'analyse histologique des foies natifs a démontré une hémorragie massive et 
extensive avec nécrose hépatocytaire à 15 heures après l'administration 
d'acétominophen. Chez les souris survivantes, une récupération complète du tissu 
hépatique a été démontrée à deux semaines post transplantation.  
 
En conclusion, les données présentées dans cette étude indiquent que les 
hépatocytes porcins peuvent être encapsulés et cryo-préservés avec maintien des 
fonctions biologiques in vitro. Après transplantation intra-péritonéale dans des souris 
avec insuffisance hépatique fulminante, les hépatocytes xenogénéiques porcins 
encapsulés ont permis le soutien des fonctions métaboliques des receveurs, sans 
nécessiter d'immuno-suppression. Ces données ont un grand potentiel pour une 
application clinique, puisque les hépatocytes porcins encapsulés pourraient être 
stockés comme décrit ici et injectés intra-péritonéalement chez des patients avec 
insuffisance hépatique fulminante. Toutefois, avant d'initier des essais cliniques, ces 
résultats doivent être confirmés dans des modèles de grands animaux. En effet, le 
modèle d’insuffisance hépatique fulminante que nous avons développé chez la 
souris est une combinaison de lésion toxique et traumatique du foie. Comme 
souvent en recherche expérimentale, la physiopathologie du modèle animal ne 
correspond pas exactement aux diverses situations cliniques et le traitement par 
transplantation cellulaire pourrait donc ne pas avoir le même effet en cas 
d’insuffisance hépatique chez l’humain.   
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Background and review of the literature 
 
Progress and challenge in hepatocyte transplantation 
 
Hepatocyte transplantation (HTx) has been proposed as an alternative to 
whole-organ transplantation to support many forms of hepatic insufficiency. Based 
on a significant body of work, the technique of HTx has recently moved into the clinic 
in order to reestablish liver function without organ transplantation or to bridge the 
time between whole-organ liver transplantation. The quality of the hepatocytes used 
for clinical cell transplantation is very important, and depends to a large extent on the 
nature of the tissue used for isolation. The collagenase perfusion technique to isolate 
hepatocytes from animal livers has been further developed for isolation of human 
hepatocytes. As the donor organ pool is a scarce resource, marginal livers 
unsuitable for transplantation and segments from reduced grafts remain the main 
source of tissue for cell isolation. Use of livers from non-heart beating donors and 
foetal livers may further increase the tissue pool. With the limited supply of available 
tissue, improvements in the cryopreservation protocols are required to maintain cell 
viability on thawing and establish hepatocyte banks. In addition, HTx has also been 
proposed as a liver-directed gene therapy for a number of inherited hepatic disorders 
by transplanting either freshly isolated hepatocytes or genetically altered 
hepatocytes.  
This short review describes briefly the progress in the techniques used to 
isolate hepatocytes from unused/rejected donor livers for transplantation, the 
common techniques used for assessment of cell viability and metabolic activity of the 
isolated hepatocytes, and also cryopreservation of hepatocytes towards 
development of cell banks. 
The liver is an important organ in the body where protein synthesis and 
metabolism of exogenous and endogenous substrates are performed. Orthotopic 
liver transplantation (OLT) is an established treatment for patients with severe acute 
and end-stage chronic liver disease. This technique requires removal of the entire 
native liver with transplantation of a high quality graft. Unfortunately, the number of 
patients who have benefited from OLT is very limited, because the shortage of donor 
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livers, and their timely availability continues to be a world-wide problem (1, 2, 3, 4). 
Many preclinical studies into HTx have suggested it has potential clinical application 
and this has formed the basis for the few human studies of HTx as an alternative 
treatment for patients with either acute liver failure or metabolic liver disease. To 
improve the methods related to hepatocyte transplantation, studies have been 
focused on hepatocyte isolation from donor livers, cell culture propagation of the 
hepatocytes, hepatocyte preservation, and genetic modification of the hepatocytes to 
provide liver-specific functions. The optimal technique may provide liver support 
while the native liver regenerates, or help in replacing the missing enzyme function in 
metabolic conditions, with the aim of avoiding liver transplantation (5, 6, 7, 8). 
 
Technique for isolation of hepatocytes 
The technique used to isolate hepatocytes was originally proposed by Berry 
and Friend (9) using a two-step collagenase perfusion method in rodent livers. This 
technique was further developed by Seglen (10) to become the two-step collagenase 
perfusion technique, as widely used in today’s practice. Modifications in the process 
of hepatocyte isolation in terms of collagenase concentration and perfusion rate 
based on the two-step collagenase perfusion method have been studied (11) and 
used to isolate human hepatocytes for clinical application (12, 13, 14).  
If a whole liver is to be perfused, cannulae are placed in the existing major 
blood vessels of the liver, and secured in place by sutures. For segments of liver, 
cannulae are placed in patent blood vessel openings on the cut surface, and secured 
by sutures. In this case, smaller blood vessel openings need to be sealed to prevent 
leakage of perfusion solutions from the cut surface. The liver tissue is perfused with 
a calcium-free buffer solution at 37 °C containing a cation-chelating agent to remove 
calcium (Ca2+) ions, leading to disruption of the desmosomal structures, which hold 
cells together. The tissue is then perfused with the buffer solution containing Ca2+ 
and collagenase to digest the tissue. The hepatocytes are separated by low speed 
centrifugation, and the hepatocyte pellets obtained are washed with ice-cold buffer 
solution to purify the cells.  
The number and quality of the isolated hepatocytes vary depending on the 
quality of the tissue used, the composition of perfusion buffer solutions, and the type 
and concentration of collagenase. Collagenase is prepared from bacteria, and 
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consists of a poorly purified blend of enzymes, which may have inconsistent 
enzymatic action, which varies from lot to lot (15). Liberase® is a new preparation of 
a highly purified blend of collagenase isoforms which have been used for preparation 
of pancreatic islets, and more recently for hepatocytes and has the advantage of 
lower bacterial contaminants. Donini et al.(16) compared Liberase® HI to 
collagenase P for preparation of porcine hepatocytes, and showed that Liberase® HI 
was as effective in the isolation of hepatocytes, and resulted in a higher cell viability.  
The sources of human hepatocytes include unused segments of donor liver 
obtained from split/reduced grafts, and whole livers considered unsuitable for 
transplantation for reasons such as excessive fat or trauma (17, 18).  Recent 
developments to increase the donor organ pool by using non-heart beating donors 
(NHBD) have also contributed towards increased availability of liver tissue for 
hepatocyte isolation. Hepatocytes obtained from good quality donor liver segments 
are the most suitable for HTx, while cells obtained from fatty livers are difficult to 
purify, tend to have lower viability and are unlikely to be satisfactory for HTx. It may 
be possible to improve the quality of cells isolated from borderline donor tissue by 
incubation in modified culture media containing additives, for example growth factors 
such as hepatocyte growth factor (HGF). HGF has protective effects on cold-
preserved fatty livers from rats (19) and was also shown to be effective in treatment 
of alcohol-induced fatty liver in rats (20). Due to the shortage of donor tissue, 
researchers have looked at other sources of human hepatocytes that is being 
evaluated is normal foetal liver obtained from unwanted pregnancies. It was shown 
that foetal hepatocytes possess metabolic (cytochrome P450) activities, and are able 
to synthesize hepatic marker proteins such as albumin. Compared to adult 
hepatocytes, foetal hepatocytes are highly proliferative in vitro, and this may 
potentially lead to enhancement of their engraftment and repopulation once 
transplanted into the liver (21). 
 
Assessment of hepatocyte viability 
Isolated hepatocytes are usually assessed immediately after 
isolation/purification using the standard trypan blue exclusion technique. Although 
this is commonly used, it does not allow detection of cells in the early stages of the 
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cell death cascade, such as observed in apoptosis. In vitro cell viability may not 
reflect cell function after transplantation in vivo. In vitro assays/tests of cell viability 
and metabolic activity are needed to characterise the quality of the isolated 
hepatocytes. The efficiency of plating or attachment of hepatocytes is considered to 
be a ‘sign’ of a good hepatocyte preparation. However, the attachment ability of 
transplanted cells may recover in vivo because of a favourable microenvironment. 
Other tests that can be used to detect viability and activity of the isolated 
hepatocytes include MTT assay, cytochrome P450 activity, protein synthesis using 
[14C]-leucine incorporation, DNA synthesis using [3H]-thymidine incorporation 
assays, and production of hepatic marker proteins such as albumin, transferrin, and 
apolipoproteins (22). Although these tests are more sensitive than trypan blue 
exclusion and reflect the cells activity and function they are usually applied to 
attached cells, and if cell suspension is used, the problem of determining which cells 
are dead remains. Ideally, viable cells should be separated e.g. by Percoll® 
centrifugation, then tested using the above assays; however, this is time consuming, 
and may lead to a decrease in the cell viability. Rapid tests need to be developed to 
assess the quality of liver tissue prior to hepatocyte isolation and for the hepatocytes 
produced to help determine their suitability for HTx. 
Primary hepatocyte culture 
One of the first requirements for both short-term and long-term culture of 
hepatocytes is good cell attachment to the culture vessel/flask. The culture vessels 
should be precoated with a suitable attachment factor/matrix such as gelatin, 
collagen type I or Matrigel® (23,24), which correspond to the in vivo extracellular 
matrix. Although there have been recent advances in culturing of hepatocytes, 
hepatocytes in culture rapidly lose their hepatocyte-specific functions within several 
days. The human hepatocytes isolated by the modified two-step collagenase 
perfusion method described above retain partial functionality for up to 4 days in cell 
culture as measured by microsomal enzyme expression, and do not proliferate. In 
the context of HTx, cells are not usually cultured beforehand. However, this is 
important when hepatocytes are to be genetically modified in vitro to enhance or 
replace activities and then be transplanted in vivo. In this case, in order to maintain 
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differentiated hepatocytes in vitro and promote intracellular metabolism, culture 
media used must be supplemented with foetal calf serum, and/or nonnutritional 
growth factors such as HGF, epidermal growth factor (EGF), insulin, and 
glucocorticoids such as dexamethasone (25, 26).  
Immortalized human hepatocytes 
Present cell culture conditions have not allowed extensive proliferation of 
primary hepatocytes. Thus the establishment of an "immortal" hepatocyte cell line 
that could be continuously grown in unlimited quantities while retaining much of the 
characteristics of differentiated hepatocytes would be highly desirable. Cell 
immortalization could be generated by transferring specific oncogenes into these 
hepatocytes (27). Immortalized human or murine hepatocyte cell lines have been 
primarily established by transfecting the simian virus 40 large T antigen or culturing 
primary hepatocytes in a collagen gel sandwich (28.29.30). Since primary 
nonimmortalized hepatocytes have been shown to demonstrate hepatocyte-specific 
functions only for a short duration, it appears that immortalized hepatocytes may be 
offered as a viable alternative for future use in HTx (31). 
 
Cryopreservation of hepatocytes  
Shortage of donor liver tissue for the isolation of hepatocytes necessitates the 
development of improved cryopreservation techniques for long-term storage of 
human hepatocytes to make best use of available hepatocytes (32).  The ultimate 
goal of any improved cryopreservation protocol is to minimise sudden intracellular 
formation of ice crystals that could result in ultrastructural damage, and thus 
maintains cell viability, attachment, and metabolic activity on thawing. Storage time 
of cryopreserved hepatocytes at temperatures well below −100 °C (e.g. liquid 
nitrogen, and −140 °C freezers) may play an important role in the quality of thawed 
cells. Most of the available protocols use dimethylsulfoxide (DMSO) in the 
cryopreservation medium, which currently appears to be the best cryoprotectant 
compared to other agents such as glycerol (33). Hengstler et al. developed a 
protocol for cryopreservation of human hepatocytes using a controlled-rate freezer, 
with rapid thawing followed by slow dilution of DMSO to avoid osmotic shock. The 
Jie MEI                                                                                                             2006 13 
cells were shown to have a reasonable level of cell viability, and ≥60% overall 
cytochrome P450 activity compared to freshly isolated hepatocytes, and these 
cryopreserved hepatocytes were used in short-term metabolism studies (34). 
Cryopreservation of hepatocytes is essential for the emergency treatment of acute 
liver failure. It is hoped this will lead to a wider use of cellular therapies in liver 
disease.  
Encapsulation of hepatocytes 
For many years, with remarkable progress in biotechnology, scientists have 
developed a micro-encapsulation method with calcium-free alginate to ensure a 
suitable environment for proper functioning of bioorganism. The encapsulation of 
human and animal cells into microcapsules benefits cells to be protected from 
environmental influences, e.g. immune system attack of a patient, or be protected 
against oxidation. For this reason, the encapsulation technology has its use in cell 
transplantation for the treatment of liver diseases.  
With this device, human hepatocytes can be encapsulated in a Barium-
Alginate capsules which can protect them from the attack of immune system. There 
are small pores on the membrane of capsules. Cells and Ab cannot pass through the 
membrane. While, hepatocytes secretions and O2, glucose, nutrients can pass 
through the membrane to maintain metabolic function (35, 36). Encapsulation of 
hepatocytes into semipermeable membranes may be a promising technique for the 
development of extracorporeal bioreactors or for transplantation of immunoinsulated 
hepatocytes for treatment of liver failure (37,38). 
 
Site of hepatocyte transplantation 
Intraportal or splenic hepatocyte transplantation 
An effective method of hepatocyte delivery to a particular site is essential to 
establish HTx as a conventional therapy. Previous studies have demonstrated 
therapeutic efficacy of HTx through a variety of liver disease models, which include 
liver failure due to the extensive liver removal or end-stage liver cirrhosis [39,40]. 
Because the host liver represents an ideal “home” for the transplanted hepatocytes 
in terms of the unique hepatic organization and interactions with nonparenchymal 
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liver cells [41], all of these experiments were conducted by infusing cells to the liver 
through intraportal or intrasplenic routes. These investigators showed that after 
hepatocyte infusion, a portion of the cells start to translocate into the space of Disse 
by disrupting the sinusoidal endothelium and finally join adjacent host hepatocytes; 
this process takes approx. 20 h to occur. In the next few days, bile canaliculi 
between the transplants and host cells are also reconstituted [42], and it is this ability 
to reconstitute new functional biliary systems that allows this method of hepatocyte 
transplantation to be applied towards diseases that have biliary secretion defects 
[43]. The spleen is also a viable target tissue for transplantation of hepatocytes since 
it offers the ability to form differentiated chord structures and reform nearly normal 
hepatic architectures [44,45]. 
One of the major limiting factors in utilizing either the intraportal or intrasplenic 
approach is the number of viable cells that can be engrafted without causing 
complications. In terms of intraportal transplantation, the major complication has 
been found to be portal vein thrombosis, which resulted in liver failure and severe 
portal hypertension, hemorrhage, and migration of cells to the lungs leading to 
pulmonary embolism, as shown in a previous study [46]. Clinical trials of intraportal 
HTx have confirmed subsequent portal hypertension and/or pulmonary dysfunction 
albeit for a transient period of time [47]. Intrasplenic transplantation has also resulted 
in similar complications, with a large proportion of hepatocytes (approx. 80%) 
migrating out of the spleen into the portal circulation [48]. 
 
Ectopic hepatocyte transplantation 
A transplantation site for the hepatocytes other than the liver or spleen is 
defined as ectopic HTx, which can potentially provide more space to transplant a 
greater number of donor hepatocytes. Moreover, it has been shown to produce fewer 
complications than transplantation through the intraportal route.  
Previous reports have transplanted hepatocytes at several different ectopic 
sites, including the intraperitoneal cavity [49], pancreas [50], under the kidney 
capsule [51], etc. However, the transplanted donor cells resulted in very short-term 
survival, which is due largely to the inadequate initial donor cell engraftment and lack 
of neovascularlization to support their survival. In order to support successful initial 
donor cell engraftment at the ectopic site, several modifications have been 
performed to provide an extracellular matrix component to act as an anchor for these 
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donor cells and would aid in prolonging hepatocyte survival and differentiation. 
Establishment of vascular network is likely required for the growth and function of the 
transplanted hepatocytes. Ajioka et al. [52] have transfected the vascular endothelial 
growth factor gene (VEGF) into the primary hepatocytes and transplanted them into 
the abdominal cavity. VEGF-transfected hepatocytes formed large colonies with 
vascular networks around the transplants. Despite these numerous modifications at 
the ectopic transplantation site, long-term survival has yet to be unequivocally 
demonstrated. In addition, for successful ectopic HTx to occur, it is important to 
maintain the supply of hepatotropic stimulation to achieve long-term survival and cell 
specific functions. The regenerative stimulus induced by performing partial 
hepatectomy results in a very minor effect on the survival of the transplants. Since 
the portal blood contains rich hormonal factors for hepatotropic stimulation, while the 
general circulation does not [53]. 
 
Clinical Experience with Hepatocyte Transplantation in Humans  
Mito et al. reported the first clinical trial in 1993 patients with chronic liver 
disease were received infusions of autologous hepatocytes isolated from partial 
hepatectomy specimens. However, there was no sign that hepatocytes were 
responsible for any clinical improvement (54). Strom et al. reviewed the human 
experience with chronic end-stage liver disease. Few conclusions can be drawn 
from this experience as to whether survival was prolonged in these patients 
because of the infused hepatocytes (55). Habibullah et al. reported 
transplantation of human fetal hepatocytes into the peritoneal space of seven 
patients with fulminant hepatic failure. Three patients of the transplanted group 
recovered from severe coagulopathy and encephalopathy. But the authors 
suggested it was still not possible to conclude that these results clearly indicated 
significant benefits of transplanted hepatocytes in patients with fulminant hepatic 
failure, but certainly this experience was suggestive of benefit (56). Like the same 
problems faced by nearly all interventional studies in acute liver failure, it is 
difficult to determine whether intervention had any effect on outcome in these 
patients. But the data mentioned above seemed to suggest a potential for 
substantially longer survival than would be expected without HTx. In addition, 
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animal studies have implied that repeated cell transplantations might be the 
optimal method to manage acute liver failure (57). For these reasons, it would 
seem that neither chronic liver disease nor acute liver failure would be the ideal 
human model with which to effectively demonstrate the efficacy of this procedure. 
Muraca et al. reported an adult with glycogen storage disease type Ia and poor 
dietary compliance. After HTx, the authors documented improved glycemic 
control but have not been able to demonstrate either engraftment or increase in 
glucose-6-phosphatase activity on liver biopsy subsequent to transplantation 
(58).  
The hepatocyte mass required to cure a liver-based metabolic disease is 
unknown, and animal studies have not been designed to answer this question 
specifically. It is to be expected that the mass required will vary according to the 
specific metabolic deficiency. In several animal models, transplanted hepatocytes 
have a proliferation advantage over the native liver cells, and liver mass 
approaching 100% can be replaced (59). Human hepatic repopulation equivalent 
to that found in the laboratory has not been clinically feasible.  In animal models 
where there is no proliferation advantage to transplanted cells, even repeated 
hepatocyte infusion is unlikely to replace more than 5% to 10% of hepatocyte 
mass (60). Calculations are vague because the total number of cells in the 
human liver has only been estimated. The number generally used is 4×109 
hepatocytes per kilogram of body weight (47). Therefore, it is probably 
reasonable only to attempt HTx in a liver-based metabolic disease where small 
increases in enzyme activity may be expected to produce a significant clinical 
result. In the cirrhotic rat model, it has been shown that only 1% to 3% of the 
estimated hepatocyte mass transplanted into the spleens improves overall liver 
function and survival. 
Long-term studies have not been carried out in animals specifically 
addressing how long transplanted cells function. After pancreatic islet 
transplantation, in many cases, there has been gradual diminishing function of 
engrafted cells (61). The same may be true after HTx. It is conceivable that 
transfused hepatocytes may not be “healthy” after isolation and may be more 
prone to apoptosis. However, there are no noninvasive ways of assessing 
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persistence of hepatocyte engraftment. Until such methods are found, this 
question will remain largely unanswered. 
It is estimated that only 20% to 30% of cells engraft into the parenchyma 
of the liver (62). Excellent viability of hepatocyte can be demonstrated ex vivo on 
the basis of trypan blue exclusion. But this does not necessarily correlate with 
successful engraftment. Clearly, it is possible with these tests to determine which 
cells will not engraft, but it is not possible to predict which ones will engraft in 
humans.  
To date, immunosuppression in cases of human HTx has been based on 
the protocols in place for liver transplantation in each institution. However, it is 
known that without adequate clinical experience with HTx, it will not be possible 
to determine optimal immunosuppression. In the future, induction of immunologic 
tolerance may be more advantageous. 
Alternatives to Primary Human Hepatocytes 
The limiting factor of HTx is fresh human hepatocytes, and there is no greater 
supply of organs from which to extract hepatocytes. In vitro proliferation to greatly 
expand isolated hepatocytes numbers is a good idea. Hepatocyte culture 
techniques, however, have not yet been developed to achieve this.  
For malignant cell lines (such as hepatoblastoma-derived HepG2 cells), there 
is a risk of inducing hepatic cancer and the metabolic phenotype of these cells is 
altered and if transplanted are unlikely to restore normal liver function. SV40 T-
antigen immortalized hepatocytes have been demonstrated to restore hepatic 
function when transplanted into animal models but carry a potential for increased 
malignant transformation (63).  
Liver-repopulation studies in animals on using mature hepatocytes: so-called 
oval cells and hepatic stem cells were reported recently (64). However, there is no 
efficient way of purifying and manipulating these cells to generate sufficient numbers 
in human transplantation. Fetal hepatocytes and fetal stem cells have been used in 
animal models but have not yet been shown to be capable of restoring normal 
hepatic function in animal models of liver failure or metabolic disease (65,66). The 
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use of multipotent adult mesenchymal bone–marrow-derived stem cells for hepatic 
repopulation in animal models has received a great deal of attention recently (67).  
The last possibility may be cells from other species, xenogeneic hepatocytes.  
If methods of using xenogeneic cells for human HTx can be devised, the lack of cells 
would be solved. Xenogeneic cells have been shown to be effective in many animal 
models in which HTx has been undertaken, including those with chronic liver 
disease. Endogenous retroviruses remain worrisome, but porcine endogenous 
retrovirus has not been shown to be a pathogen in humans (68).  It is foreseeable 
that HTx using animal hepatocytes may be the most feasible method of exploring the 
potential human application of this technology. 
The promise of isolated HTx as a treatment for human liver diseases has 
grown stronger with recent animal studies and the limited human data. Shortage of 
transplantable hepatocytes should be solved to finally achieve the HTx in human. 
Cadaveric whole livers are not going to become any more available than they are 
today. Cell culture and proliferation studies on primary hepatocytes and cell lines 
should be carried on in the future. 
 
Future prospects 
The considerable efforts that basic and clinical researchers have undertaken 
in the past several years have laid the foundation for the better understanding 
regarding the methods needed for HTx, such as hepatocellular isolation, cell culture 
propagation and viability, immunosuppression, and hepatic gene transduction, for 
the utilization in therapeutic protocols. At the present time, however, this approach is 
still in the early stages of development to be used as a clinical procedure for liver 
disorders. Nevertheless, there have been several successful clinical reports 
discussing the beneficial effects using this approach in both environmentally and 
genetically affected individuals with either FHF with encephalopathy stage 3. It is 
important to note that the HTx procedure is much less invasive and less expensive 
for patients than OLT. With further modifications, people believe that HTx could offer 
beneficial effects to a number of patients with liver diseases, who are awaiting OLT, 
as a viable alternative therapy. 
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Abstract 
Aim 
The aim of this study was to establish hepatocyte isolation in pigs, and to 
evaluate in vitro and in vivo functions of isolated hepatocytes after encapsulation, 
cryopreservation, and xenotransplantation (Tx) into mice with fulminant liver failure 
(FLF). 
Methods 
Porcine hepatocytes were isolated from normal liver tissue by collagenase 
perfusion and digestion. Hepatocytes were encapsulated in 400micron alginate-PLL-
alginate membranes and cryopreserved using a computerized device. In vitro, free 
and encapsulated hepatocytes (cryopreserved or freshly isolated) were cultured in 
albumin-free medium and albumin production was measured by enzyme linked-
immunoadsorbent assay (ELISA). In vivo, a model of FLF was established in 
C57/BL6 mice by acetaminophen administration (700 mg/kg i.p) followed 15 hours 
later by a 30% hepatectomy. Microencapsulated (cryopreserved or freshly isolated) 
hepatocytes were transplanted intraperitoneally to mice with FLF and the following 
experimental groups were performed: Group 1 (N=11) Tx of empty capsules; Group 
2 (N=12) Tx of free primary porcine hepatocytes; Group 3 (N=36) Tx of fresh 
encapsulated porcine hepatocytes; Group 4 (N=38) Tx of cryopreserved 
encapsulated porcine hepatocytes; Animals were euthanized at regular intervals and 
histopathology of microcapsules and liver tissue was obtained.  
Results 
In vitro, cryopreserved or fresh encapsulated porcine hepatocytes showed a 
progressively decreasing albumin secretion over one week. In vivo, in Groups 1 and 
2, survival remained unmodified (18% and 25% respectively). In Groups 3 and 4, Tx 
of fresh or cryopreserved encapsulated porcine hepatocytes significantly increased 
survival rate to 75% and 68%, respectively (P<0.05). Histopathology of native liver 
tissue demonstrated massive hemorrhage and extensive hepatocytes necrosis at 15 
hours after acetaminophen administration. In contrast, surviving mice showed 
complete recovery of native liver tissue 2 weeks post-transplantation. 
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Conclusions 
Primary porcine hepatocytes maintained synthetic functions after 
encapsulation and cryopreservation. After induction of FLF in mice, intraperitoneal 
Tx of encapsulated xenogeneic hepatocytes (fresh or cryopreserved) significantly 
improved survival. These results indicate that naïve porcine hepatocytes can 
successfully be isolated, encapsulated, cultured, stored using cryopreservation, and 
be transplanted into xenogeneic recipients with liver failure and sustain liver 
metabolic functions. 
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Introduction 
 
The most effective therapy for acute or chronic hepatic failure is orthotopic liver 
transplantation (OLT). The first case was performed in human in 1963. With 4-year 
survival rates that exceed 70% for most clinical indications (1), OLT still holds the 
best therapeutic promise for thousands of patients each year. However, the number 
of patients who have benefited from OLT is very limited. Because the shortage of 
livers has given rise to transplant waiting lists that are several years long. Yet it has 
also stimulated intensive research to identify novel therapies for liver disease. 
Hepatocyte transplantation, a “novel” therapy takes advantage of the tremendous 
proliferative capacity of the differentiated hepatocyte. 
Liver is one of the organs of the earliest cell transplantation experiment. 
Hepatocyte isolation started in the mid-1960s by Howard et al (2). The other 
researchers had transplanted normal hepatocytes into Gunn rat liver in 1976, the rat 
carried a deficient bilirubin-VDP-glucuronosyltransferase gene, the gene deficiency 
results in unconjugated hyperbilirubinemia, such as Crigler-Najjar syndrome type I in 
human. The result showed that plasma bilirubin level of rat continuously fall 50%. 
Recently, cellular transplantation has been used successfully in rodent (3-5) and 
primate (6,7) models using primary hepatocytes, the chief function cells of the liver. 
Hepatocyte transplantation involves the transfer of normal hepatocytes into 
diseased liver, by injecting isolated hepectocytes into the spleen or splenic artery or 
directly into the portal vein (8). The other researchers have found that ectopic 
transplantation of the hepatocytes (i.e. transplantation of hepatocytes to areas of the 
body other than the liver such as under the kidney capsule, subcutaneous space, 
and peritoneal cavity) can also have therapeutic efficacy (9). They also found that 
administration of 104 liver cells could replace more than 80% of the liver, indication 
that donor hepatocytes were capable of at least 12 rounds of cell division (8). 
Due to the successes of hepatocyte transplantation in animals, hepatocyte 
transplantation has accessed the stage of clinical research. The first report was in 
1994 (10). Among potentially significant applications of cell transplantation are 
included provisions of metabolic support in acute or chronic live failure and definitive 
treatment of inherited metabolic disorders. Moreover, Hepatocytes are an excellent 
vehicle for ex vivo gene therapy. 
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In recent studies, clinical research of the effect of hepatocyte transplantation 
therapy on liver failure is very limited. At least, we can get messages from the 
following 1. Hepatocyte transplantation can prolong survival, and can be used 
clinically to “bridge” patients to whole organ transplantation. 2. Hepatocyte 
transplantation can provoke regeneration of liver. Such that partial patients regained 
their normal physiological hepatic function without having to undergo orthotopic liver 
transplantation.  3. Hepatocytes transplantation is safe (11-13). Hepatocytes 
transplantation is limited in clinical application because transplanted hepatocytes 
cannot proliferation in the recipient livers, due to proliferation function of adult 
hepatocyte is weak. 
As considering the severe shortage of human livers for hepatocyte isolation, it is 
important to looking for new source of hepatocytes. There are three likely new 
sources of hepatocytes that could meet the needs of the transplant community. 1. 
Immortalized hepatocytes. 2. Hepatocytes derived from stem or fetal cells. 3. 
Xenogenic hepatocytes (especially coming from particular porcine hepatocytes, 
which were incubated in no pathogen environment).  
Hepatocyte cell availability could become unlimited with the use of xenogeneic 
hepatocytes. Investigators abandon human cells entirely in favor of an investigation 
of xenotransplants with porcine hepatocytes into a rat model of terminal cirrhosis.  
Transplants consisted of 50 million porcine hepatocytes injected into the spleen 
while the splenic veins and arteries were occluded to insure that most of the 
transplanted cells remained in the spleen. The rats that received hepatocyte 
transplants showed significant improvements in their encephalopathy scores and 
plasma bilirubin, albumin and ammonia levels compared with untreated controls. 
Porcine hepatocytes were as effective as syngenic rat or hepatocytes in the 
correction of liver function in these animals (14). 
Recently porcine hepatocyte have been utilized for bioartificial liver (BAL) 
treatments. Because pigs have similar physiology to humans and one liver can 
provide enough hepatocytes for several BAL treatments. Although nonhuman 
primates are genetically closer to human, the pig appears to be the most suitable 
source of organs for humans (15). The implantation of xenogeneic tissue has 
provoked ethical and epidemiological controversies (16). Transmission of porcine 
endogenous retroviruses (PERV) from porcine cell lines or endothelial cells to 
human cells has been demonstrated in vitro (17, 18). However, PERV transmission 
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into humans has never been observed and it has not been possible to demonstrate 
any viral transmission, let alone clinical infection or disease in patients who had been 
exposed to living porcine tissues (19, 20).  
The major obstacle to successful xenotransplantation is the immunological 
incompatibility between pigs and humans. The major xenoantigen responsible for 
rejection of porcine grafts in humans has been identified as the carbohydrate 
epitope, galactose α1-3galactose (Gal) (21). All mammals, except humans, apes and 
Old World monkeys, express this oligosaccharide on the surface of their vascular 
endothelial cells. Primates that do not synthesize this carbohydrate begin to produce 
antibodies directed against it during neonatal life, as they do to ABO blood type 
antigens. These natural antibodies initiate the hyperacute rejection of 
xenotransplanted organs by activating complement and coagulation and inducing 
thrombosis and hemorrhage in the graft (22).  
Investigators have focused on the use of porcine hepatocytes. Several issues 
should be addressed to facilitate such cell-based biological therapies, these include: 
1. Establishment of an effective cell isolation procedure for functional and uniform 
porcine hepatocyte preparation. 2. Achievement of an efficient gene transfer 
technique into the isolated and cultured cells. 3. Achievement of an efficient cold 
storage and cryopreservation method of porcine hepatocytes. 4. Establishment of 
models allowing assessment of safety and effectiveness of such cell therapy (23, 
24). 
Therefore, in the present study, we investigated an efficient procedure for 
isolating hepatocytes from a surgically resected segment of the pig liver, established 
an cold-preserved method of porcine hepatocytes, developed a technique of 
encapsulation of porcine hepatocytes. The aim of this present study was to test in 
vitro and in vivo the function of primary porcine hepatocytes after 
microencapsulation, cryopreservation and xenotransplantation into mice with 
fulminant liver failure (FLF). A model of FLF using for porcine hepatocytes 
transplantation was established in C57/BL6 mice by acetaminophen administration 
followed 15 hours later by a 30% hepatectomy, which would allow the study of 
porcine hepatocyte specific function.  
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Materials and Methods 
A. Isolation Porcine Hepatocytes 
Materials: 
1. Small pig: 10-15Kg 
2. Steriled perfusion machine  
3. O2 bottle 
4. Nylon Mesh (Size 100µm, BD Falcon™ Cell Strainers, 352360) 
5. UW solution (Viaspan) 500ml 
6. Liver Perfusion Medium (1X) (Invitrogen, Switzerland, Cat. No. 17701-038) 
Volume: 1-2L 
7. Liver Digest Medium (1X) (Invitrogen, Switzerland, Cat. No.17703-034) 
Volume: 0.5-1L 
8. Preparation of culture media 
(1) Transport medium (TM) 
To 494.5 ml L-15 medium add 0.05 ml of fungizone (2.5mg/ml) and 5ml of 
penicillin/streptomycin to give a final concentration of 0.25µg/ml, 100units/ml 
and 100µg/ml, respectively. Mix well, filter sterilize and store at 4°C. 
(2) Serum-containing hormonally defined medium (SHDM) 
To 440 ml Williams E medium add the following to give a final concentration 
of: 50 ml FBS (10%), 5 ml of penicillin (100units/ml)/streptomycin (100µg/ml), 
72ul (100IU/ml) insulin (10-7 M), 5ul (0.1M) dexamethasone (10 –6 M) and 5 ml 
of 2.5µg/ml EGF (25ng/ml). Mix well, filter sterilize and store at 4°C. 
(3) Hormonally defined medium (HDM) 
To 490 ml Williams E medium add the following to give a final concentration of: 
5 ml of penicillin (100 units/ml)/streptomycin (100ug/ml), 72ul (100IU/ml) 
insulin (10 –7M), 5ul (0.1M) dexamethasone (10 –6M) and 5ml of 2.5µg/ml EGF 
(25ng/ml). Mix well, filter sterilize and store at 4°C. 
9. 60 x 15 mm Cell Culture Dish (Area: 28.26cm2), standard tissue-culture 
treated (BD Biosciences Discovery Labware, 353004) 
10. 100 x 20 mm Standard Cell Culture Dish, standard tissue-culture treated (BD 
Biosciences Discovery Labware, 353003) 
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11. Trypan Blue Stain, 0.4% (Invitrogen, Switzerland, Cat. No. 15250-061) 
12. Cell Culture Freezing Medium-Dimethylsulphoxide (DMSO) (1X), (Invitrogen, 
Switzerland, Cat. No. 11101-011) 
13. L-15 medium (Invitrogen, Switzerland, Cat. No. 11415-049) 
14. Penicillin-Streptomycin-Glutamine (100X), liquid (Invitrogen, Switzerland, Cat. 
No. 10378-016) 
15. Fungizone (Bristol-Myers Squibb GmbH, 6341 Baar, Switzerland) 
16. Foetal Bovine Serum (FBS) (Invitrogen, Switzerland, Cat. No. 10108-165) 
17. Insulin (Huminsulin, HI0310, LILLY FRANCE S.A.S.) 
Insulin:  100IU/ml =100,000IU/L=100,000,000mIU/L (in stock) 
1mIU/L=6.965pmol/L 
100,000,000mIU/L=696,500,000pmol/L=696,500nmol/L=696.5umol/L 
500ml culture medium insulin 10-7 M (0.1umol/L) 
x=0.0717875ml=71.79ul=72ul 
Take 72ul insulin (100IU/ml) to 500ml culture medium 
18. Dexamethasone (Sigma, D4902) 
Dexamethasone (25mg) MW: 392.74 
392.74g in 1000ml is 1M, 39.274g in 1000ml is 0.1M 
0.025g in 636.55ul water is 0.1M (in stock) 
dexamethasone final (10 –6 M=1uM) 
500ml culture medium insulin dexamethasone final (10 –6 M=1uM) 
x=0.005ml=5ul 
Take 5ul dexamethasone (0.1M) to 500ml culture medium 
19. EGF Epidermal Growth Factor (Sigma, Switzerland, E4127) 
20. Surgical instruments 
21. Timer 
22. Water bath 
Methods: 
I. Partial resection of a Porcine Liver 
Under general anesthesia, a midline incision was made in the upper abdomen 
and the liver was exposed. After ligation blood vessels in the root of the lateral 
lobe of the liver, the hepatic lateral segment was surgically resected in a sterile 
manner and subjected to hepatocyte isolation. 
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UW solution perfusion of the hepatic lateral segment: 
(1) Ligation of hepatic artery 
(2) Put a suture beneath the portal vein, but don’t ligate 
(3) Ligation of right hepatic portal vein and right bile duct 
(4)  Ligation of left bile duct  
(5) Ligation of portal vein 
(6) Cannulation of left portal vein 
(7) Perfusion the hepatic lateral segment (left lateral lobe) with UW solution 
(8) Keep the resected lateral segment in UW solution 
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II. Isolation of porcine hepatocytes  
(1) Cannulate the hepatic vein with silicone tubing (for inflow) and secure it carefully 
with a ligature, making sure that the tubing stays in place throughout the procedure. 
Buffer is transferred using a peristaltic pump. Other silicone tubing is used for 
outflow. Perfusates for outflow are drawn from a Petridish into an Erlenmeyer flask.  
 
(2) Maintain the perfusion buffer at 37℃ and saturate these buffers containing 100% 
oxygen just before use. Start the perfusion at a rate of 60 ml/min for 15 min using 
perfusion buffer: Hepatocyte Liver Perfusion Medium (1X) (Invitrogen, Switzerland, 
Cat. No. 17701-038) 
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(3) Perfuse the liver with Liver Digest Medium (1X) (Invitrogen, Switzerland, Cat. 
No.17703-034) at a rate of 60 ml/min for 10 min.  
(4) The perfused liver is aseptically removed and transfer to a sterile glass Petridish 
with cold L-15 Medium, then transferred to the cell culture laboratory on ice.  
(5) Cut the liver carefully into 2 mm pieces using scalpel blades.  
(6) Transfer the dissected liver tissue to a Erlenmeyer flask containing 200 ml 
suspension buffer (Hepatocyte Wash Medium (1X) Invitrogen, Switzerland, Cat. No. 
17704-024).  
(7) Shake the flask at 10 oscillations/min for 25 min at 37℃.  
(8) Filter the cell suspension through 100 μm nylon mesh to obtain a single cell 
suspension.  
(9) Centrifuge the single cell suspension at 60×g for 2 min at 4℃, discard the 
supernatant and resuspend the cell pellet in Hepatocyte Wash Medium. 
(10) Repeat step 9 three or four times by centrifuging at 60×g for 1 min.  
III. Purification of Hepatocytes 
For the Percoll : 
(1) Make a 60% Percoll: For 100ml, 54 ml of commercial Percoll (pharmacia)+ 6 
ml 10X calcium and magnesium free-PBS+40 ml of  Hepatocyte Wash 
Medium. 
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(2) Mixed 50 ml of the 60% percoll+50 ml hepatocyte suspension solution. 
(3) Centrifuge at 76×g for 5 min at 4℃.  
(4) Wash the resultant cell pellet twice with Hepatocyte Wash Medium by 
centrifuging at 76×g for 5 min at 4℃. The hepatocytes were used in primary 
culture, encapsulation and transplantation. 
(5) rpm=(g/(1.12 x Rmm x 10-6))-2 (Centrifuge Machine : HETTICH  D-7200 in lab 
of Transplantion Cellulare) 
 
 50ml Falcon 50ml Falcon 250ml Conical 250ml Conical 
 60g 76g 60g 76g 
Rmm (Radius) 195mm 195mm 235mm 235mm 
rmp 524 590 477 537 
IV. Determination of Cell Viability  
A.  Make a 1:10 dilution of trypan blue solution with 1X PBS buffer.  
B.  Make two 1:5 dilutions of the above cell suspension with the diluted 
trypan blue solution. (i.e. 40 ul of trypan blue solution + 10 ul of cells 
into an eppendorf tube).  
C.  Wait for about one minute, then immediately pipette 10 ul per tube into 
separate chambers of a hemacytometer.  
D.  Observe the cells under the microscope (100X magnification).  
E.  Count the total number of live cells (clear cells) and the dead cells 
(blue cells) in quadrants; A, B, C, D, for each chamber (each quadrant 
has 16 small squares, each separated by triple lines, the middle one of 
which is the boundary). A B D C  
A   B 
      
D   C 
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F.  Calculate the % viability and average cells/ml (c/ml*e6) concentration 
below.  
  
Cell Number  
(Chamber I) 
Cell number  
(Chamber II) 
%Viable 
(I)  
%Viable 
(II) 
c/mL*e6 (I) c/mL*e6 (II)  
Avg. 
Viable 
Avg. 
cells/mL*e6  
Dead       
Viable                 
% Viability = { live cells/ total cell (live+dead)} x 100  
Viable Cells/ml x 106 = Viable Cell No./4 x (Cell Dilution Factor) x 104  
B.  Primary culture of porcine hepatocytes in monolayers 
1. Suspend the cell pellet obtained above, parenchymal fraction, in a 
medium, SHDM. 
2. Count cell number of isolated hepatocytes and test viability by trypan 
blue exclusion. 
3. Inoculate 2 ml of cell suspension at 1.25 х10 5 cells/ml (5.6 х 10 4 
cells/cm2) into each well of 12 well microplates for cell culture. 
4. Next day, switch the medium to HDM. 
5. Maintain the cells at 37°c in a humidified incubator with 5% CO2 in air. 
6. The culture medium was changed, collected every day and stored at –
20°C for assessment of albumin secretion by ELISA (BETHYL, 
Lucerne, Switzerland).  
C. Encapsulation of porcine hepatocytes 
I . Mechanism of encapsulation 
For encapsulation of porcine hepatocytes, we used a semi-automated 
encapsulation device: ENCAPSULATOR (Inotech, Dottikon, Switzerland), which 
designed for rapid encapsulation of animal cells in alginate-polylysine-alginate 
membranes. 
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The encapsulation is based on the observation that alginate polymerizes 
immediately in the presence of Ca-ions. If a mixture of alginate and porcine 
hepatocytes is dropped as beads into a Ca-solution, the beads will maintain the 
shape and the porcine hepatocytes are captured in the formed three-dimentional Ca-
alginate structure. To the alginate beads, poly-L-lysine solution is added, which 
reacts with the surface of the alginate bead forming a very stable alginate-polylysine 
membrane. Unreacted amino groups of the poly-L-lysine are neutralized with an 
outer layer of alginate. The linkage between the basic groups of poly-L-lysine and 
the acidic groups of alginate is so strong, that the core alginate can be 
depolymerized with citrate leaving the porcine hepatocytes enclosed in a thin 
alginate-polylysine-alginate membrane. 
I I . Materials of encapsulation 
(1) 1.5% sodium-alginate solution, 60 ml  
(2) 20x polymerization solution, 60 ml  
(3) 20x MOPS washing-buffer, 225 ml   
(4) 20x depolymerization solution, 40 ml 
(5) Poly-L-Lysine, 190 mg 
I I I . Preparation of the solutions for one encapsulation 
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(1) 10 ml  1.5% sodium alginate solution: 
 Composition: 1.5% Na-Alginate, 10mM MOPS + 0.85% NaCl; pH = 7.3 - 7.4 
(2) 225 ml   Polymerization solution: 
 Transfer 11.25 ml of 20x Polymerization solution in a flask and add  
 213.75 ml high quality water. 
 Composition:   10mM MOPS + 100mM CaCl2 
(3) 900 ml MOPS washing-buffer: 
 Transfer 45 ml of 20x MOPS washing-buffer in a flask and add 855 ml high   
 quality water. 
 Composition: 10 mM MOPS + 0.85% NaCl. 
(4) 75 ml PLL-solution: 
 Dissolve 37.5 mg Poly-L-Lysine in 75ml MOPS washing-buffer. 
 Composition: 0.05% Poly-L-Lysine MW 15'000 - 30'000, 10 mM MOPS +  
 100 mM CaCl2. 
(5) 100 ml 0.03% alginate solution: 
 Transfer 2ml of 1.5% sodium-alginate solution in a flask and add 98 ml MOPS 
 washing-buffer 
 Composition: 0.03% NaAlginate, 10mM MOPS + 0.85% NaCl. 
(6) 150 ml depolymerization solution: 
Transfer 7.5 ml of 20 x depolymerization solution in a flask and add 142.5 ml high 
quality water. 
 Composition: 50 mM Na3Citrate, 10mM MOPS + 0.45% NaCl. 
(7) 50 ml cell culture medium: 
 Prepare 50 ml of the appropriate cell culture medium.  
IV.  Procedure of encapsulation 
(1) Fill the autoclaved reaction vessel of the ENCAPSULATION with 225 ml 
polymerization solution. 
(2) A cell culture with ca. 6 x 106 cells (or according to personal need) is centrifuged 
and the pellet is suspended in 2 ml sterile MOPS washing-buffer and mixed with 10 
Jie MEI                                                                                                             2006 41 
ml 1.5% sodium-alginate solution. Give care that no or few air-bubbles are 
introduced during mixing. 
(3) Fill a 20 ml syringe with the cell-alginate suspension and fix the syringe to the 
working container in a laminar air bench. 
(4) Fix the working container to the ENCAPSULATOR, which is placed on the bench, 
and start bead formation. Proposed settings for the ENCAPSULATOR, with the 
200µm nozzle are: flow rate: 520ml/h, frequency:1480-1520Hz 
(5) Hardening for 5 min. in the polymerization solution. 
(6) Withdraw the polymerization solution. 
(7) Add 75ml 0.05% PLL-solution and let form the PLL-alginate membrane for 10 min. 
(8) Withdraw the 0.05% PLL-solution. 
(9) 1 x washing with 100ml MOPS washing-buffer for 1 min. 1 x washing with 150ml 
MOPS washing-buffer for 5 min. 
(10) Add 100ml 0.03% alginate solution and let form the outer alginate membrane for 5 
min. 
(11) Withdraw the 0.03% Alginate solution. 
(12) 1 x washing with 150ml MOPS washing-buffer for 1 min. 
(13) Add 150ml depolymerization solution and dissolve the core alginate for 10 min. 
(14) Withdraw the depolymerization solution. 
(15) 1 x washing with 100 ml MOPS washing-buffer for 1min. 1 x washing with 
150 ml MOPS washing-buffer for 5 min. 
(16) Resuspend the microcapsules in 50ml cell culture medium and transfer 
them into the collection vessel. 
(17) Cultivate the encapsulated cells in hormonally defined medium (HDM) 
24hours before transplantation. 
D. Cryopreservation, thawing, and culture of 
encapsulated porcine hepatocytes 
After addition of 10% (v/v) DMSO (Merck Co., USA) and 10% newborn 
bovine serum (NBS, Sigma Chemical Co., USA), suspensions of freshly 
isolated and encapsulated porcine hepatocytes in the supplemented culture 
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medium were transferred into 2 ml cryogenic tubes at 1 x 107 cells/ml and 
placed in the freezing chamber of a programmable freezing unit (Kryo 10 
series III, Planer, UK) for cryopreservation by a computerized rate-controlled 
freezing program. The sample temperature was reduced at 1°C/min from 4 to 
0°C, then reduced at 0.5°C/min from 0 to -11°C, kept at -11°C for 15 min, and 
then reduced at 3°C/min from -11 to -80°C. Finally, the cryogenic tubes were 
stored in liquid nitrogen for 10 days. The encapsulated porcine hepatocytes 
(capsules) were rapidly thawed by immersing the cryogenic tubes in a 37°C 
waterbath (<1 min), and the capsules were gently washed by sedimentation 3 
times with Hanks solution. One part capsules were resuspended in 
supplemented serum-free culture medium, as specified above, and incubated 
at 37°C in 5% (v/v) CO2 for 7 days. The culture medium was changed, 
collected every day and stored at –20°C for assessment of albumin secretion 
by ELISA (BETHYL, Lucerne, Switzerland). The other parts of cryopreserved 
encapsulated porcine hepatocytes were used for in vivo transplantation. 
 
E.  Procedures of ELISA for Porcine Albumin Analysis 
I. Buffer Preparation  
(1) Coating Buffer  
Dissolve the contents of 1 capsule in 100 ml of distilled water = 0.05 M carbonate-
bicarbonate, pH 9.6. (Carbonate-bicarbonate buffer capsules, Sigma Chemical 
#C3041) 
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(2) Wash Solution  
Dissolve one packet in 1 L of distilled water. (50 mM Tris buffered saline, pH 8.0, 
0.05% Tween 20; Sigma Chemical # T9039) 
(3) Postcoat Solution  
Dissolve one packet in 1 L of distilled water. (50 mM Tris buffered saline, pH 8.0, 1% 
BSA; Sigma Chemical # T6789) 
(4) Sample/Conjugate Diluent  
Add 0.5 ml to 100 ml Postcoat Solution for use as Sample and Conjugate Diluent. 
(Use Postcoat Solution plus 10% Tween 20; Sigma Chemical # P7949) 
(5) Enzyme Substrate  
Mix equal volumes of each reagent. (TMB Peroxidase Substrate & Peroxidase 
Solution B; Kirkegaard & Perry) 
(6) Stopping Solution 
2 M H2SO4  
 
II. Step-by-Step Method (all steps at room temperature.)  
(1) Coat with Capture Antibody  
(i) Determine the number of single wells needed. Standards, samples, blanks 
and/or controls should be analyzed in duplicate. Insert the required number of 
microtiter well strips into a holder.  
(ii) Dilute 1µl capture antibody (A100-110A) to 100 µl Coating Buffer for each 
well to be coated.  
(iii) Incubate coated plate for 60 minutes.  
(iv) After incubation, aspirate the Capture Antibody solution from each well  
(v) Wash each well with Wash Solution as follows:  
(a) Fill each well with Wash Solution  
(b) Remove Wash Solution by aspiration  
(c) Repeat for a total of 3 washes.  
(2) Blocking (Postcoat)  
(i) Add 200 µl of Blocking (Postcoat) Solution to each well.  
(ii) Incubate 30 minutes.  
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(iii) After incubation, remove the Blocking (Postcoat) Solution and wash 
each well three times as in Step (1).  
(3) Standards and Samples  
(i) Dilute the standards in Sample Diluent according to the chart below:  
 
Step ng/ml 
Calibrator RS10-
107-3 
Sample Diluent 
0 10,000 5 µl 25 ml 
1 500 1 ml from step 0 19 ml 
2 250 1 ml from step 1 1 ml 
3 125 1 ml from step 2 1 ml 
4 62.5 1 ml from step 3 1 ml 
5 31.25 1 ml from step 4 1 ml 
6 15.625 1 ml from step 5 1 ml 
7 7.8 1 ml from step 6 1 ml 
 
(ii) Dilute the samples, based on the expected concentration of the 
analyte, to fall within the concentration range of the standards.  
(iii) Transfer 100 µl of standard or sample to assigned wells.  
(iv) Incubate plate 60 minutes.  
(v) After incubation, remove samples and standards and wash each well 5 
times as in Step (1).  
(4) HRP Detection Antibody  
(i) Dilute the HRP Conjugate (A100-110P) in Conjugate Diluent. 
Recommended starting dilution is 1:100,000 with a range of 1:10,000 to 
1:200,000.  
(ii) Transfer 100 µl to each well.  
(iii) Incubate 60 minutes.  
(iv) After incubation, remove HRP Conjugate and wash each well 5 times 
as in Step (1).  
(5) Enzyme Substrate Reaction  
(i) Using TMB, mix equal volumes of the two-substrate reagents.  
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(ii) Transfer 100 µl of substrate solution to each well.  
(iii) Incubate plate 5 - 30 minutes.  
(iv) To stop theTMB reaction, apply 100 µl of 2 M H2SO4 to each well. 
(v) Using a microtiter plate reader, read the plate at the wavelength 450 
nm for TMB.   (ELISA reader: Labsystems Type 351 Finland, Filter 450nm) 
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F.  Induction of fulminant liver failure 
A model of fulminant liver failure was established in C57/BL6 mice by 
acetaminophen administration (700 mg/kg i.p, 12-15 hours before Tx) and 30% 
hepatectomy at time of Tx. This model can achieve a mortality of >80%.    
 
Animal Model of Fulminant Liver Failure
Acetaminophen         +
700 mg/kg i.p.
- 15 hours 
Hepatectomy 30% 
C57BL/6 mice
>Mortality80%
Parietal surface Visceral surface
 
G. Experimental groups and encapsulated hepatocytes 
xenotransplantation 
Microencapsulated hepatocytes (cryopreserved or non-cryopreserved) were 
transplanted intraperitoneally (>50x106 hepatocytes per mouse). The following 
experimental groups were performed: Group 1 (N=11) Tx of empty capsules; Group 
2 (N=12) Tx of free primary porcine hepatocytes; Group 3 (N=36) Tx of encapsulated 
porcine hepatocytes; Group 4 (N=38) Tx of cryopreserved encapsulated porcine 
hepatocytes;  
For intraperitoneal free and encapsulated porcine hepatocytes 
transplantation, a small surgical incision was made in the middle line of mouse’s 
flank under anesthesia, 30% hepatectomy was done by removing the left lateral lobe 
by ligation. >50x106 free and encapsulated hepatocytes (capsules) suspended in 3ml 
Hank’s solution were injected gentlely through an 18G needle into the abdominal 
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cavity. After surgery, animals were attended under an infrared light to recover from 
anesthesia.  
H.  Survival follow up and histology 
In each group, mouse survivals were followed up at different time point, some 
animals were euthanized at regular intervals and histopathology of microcapsules 
and liver tissue were performed. 
I . Statistical analysis 
Statistical analysis was performed on personal computer using STATISTICA 
(STATISTICA 5.5 Software for Windows, Statsoft Inc, Tulsa, OK, USA). Survival 
curves were calculated by Kaplan and Meier method and analyzed with Х2 test. A p-
value inferior to 0.05 was considered statistically significant.  
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Results 
A.1ST time of porcine hepatocytes isolation 
1. Total hepatocytes after isolation and purification: 756 X 106 cells 
2. Pig liver: 126g 
3. 6 X 106 cells per gram of liver tissue 
4. Viability of isolated hepatocytes: 64% 
  
Cell Number  
(Chamber I) 
Cell number  
(Chamber II) 
%Viable 
(I)  
%Viable 
(II) 
c/mL*e6 (I) c/mL*e6 (II)  
Avg. 
Viable 
Avg. 
cells/mL*e6  
Dead 26  18    
Viable  37  40  59%  69% 7.88  7.25 64%  7.56  
 
5. In vitro albumin secretion  
ELISA  
OD=Optical Density   
CM=Culture Medium 
Sample Dilution 1:20 
Standard Pig 
Reference Serum 
Albumin 
(OD=Optical 
Density) 
CM 
with 
FBS 
CM 
without 
FBS 
 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
 0.044 0.044 2.364 2.074 1.910 1.787 1.558 0.923 0.738 
2.82 (500ng/ml) 0.044 0.043 2.122 2.140 2.036 1.979 1.484 0.959 0.758 
2.415 (250ng/ml) 0.044 0.044 2.257 1.956 1.982 1.655 1.671 0.873 0.638 
1.697 (125ng/ml) 0.045 0.045 
P
rim
ary P
orcine 
H
epatocyte 2.065 1.845 1.640 1.583 1.231 0.901 0.592 
0.924 (62.5ng/ml) 0.048 0.048 2.744 2.744 2.864 2.823 1.846 0.700 0.535 
0.552 (31.25ng/ml) 0.046 0.046 2.745 2.694 2.745 2.607 1.985 0.735 0.521 
0.264 (15.625ng/ml) 0.045 0.044 2.741 2.805 2.880 2.741 1.960 0.714 0.504 
0.146 (7.8ng/ml) 0.046 0.045 
E
ncapsulated P
orcine 
H
epatocyte 2.884 2.963 2.935 2.449 1.867 0.630 0.535 
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Standard Pig Reference Serum Albumin
y = 0.0055x + 0.4827
R2 = 0.8508
0
0.5
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2
2.5
3
3.5
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Concentration(ng/ml)
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ti
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a
l 
d
e
n
s
it
y
(4
5
0
 n
m
)
OD
Linear (OD)
 
X (concentration (ng/ml) = (Y (OD) – 0.4827) / 0.0055 
  Day1 Day2 Day3 Day4 Day5 Day6 Day7 
Primary 
Porcine 
Hepatocyte 
2.2020 2.0038 1.8920 1.7510 1.4860 0.9140 0.6815 
Average of OD  
(Y) Encapsulated 
Porcine 
Hepatocyte 
2.7785 2.8015 2.8560 2.6550 1.9145 0.6948 0.5237 
Primary 
Porcine 
Hepatocyte 
312.600 276.554 256.236 230.600 182.418 78.418 36.145 
Concentration 
(ng/ml) (X) Encapsulated 
Porcine 
Hepatocyte 
417.418 421.600 431.509 394.963 260.327 38.554 7.455 
Primary 
Porcine 
Hepatocyte 
6252 5531 5125 4612 3648 1568 723 
Final Actual 
Concentration 
(ng/ml) 
Sample 
Dilution 1:20 
Encapsulated 
Porcine 
Hepatocyte 
8348 8432 8630 7899 5207 771 149 
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6. In vivo studies 
Time after Tx 
No. of 
acute 
liver 
failure 
C57BL/6 
mouse 
Hours 
12 
Hours 
24 
Hours 
36 
Hours 
48 
Hours 
60 
Hours 
72 
Hours 
96 
Day 
5 
Day 
6 
Day 
7 
Day 
10 
Day 
14 
Survival 
rate 
Tx of fresh 
encapsulated 
porcine 
hepatocytes 
5 5 5 4 4 3 3 3 3 3 3 3 3 60% 
Tx of 
cryopreserved 
encapsulated 
porcine 
hepatocytes 
7 7 6 6 5 5 5 5 5 5 5 5 5 71% 
B.  2nd time of porcine hepatocytes isolation 
1. Total hepatocytes after isolation and purification:  1175X 106 cells 
2. Pig liver: 168g 
3.  6.99 X 106 cells per gram of liver tissue 
4. Viability of isolated hepatocytes: 81% 
 
  
Cell Number  
(Chamber I) 
Cell number  
(Chamber II) 
%Viable 
(I)  
%Viable 
(II) 
c/mL*e6 (I) c/mL*e6 (II)  
Avg. 
Viable 
Avg. 
cells/mL*e6  
Dead 4 5   
Viable 17 21 81% 81% 10.5 13 81% 11.75 
 
5. In vitro albumin secretion  
ELISA  
OD=Optical Density   
CM=Culture Medium 
Sample Dilution 1:20 
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Standard Pig 
Reference Serum 
Albumin 
(OD=Optical 
Density) 
CM 
with 
FBS 
CM 
without 
FBS 
 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
 0.055 0.059 2.201 2.262 2. 178 1.603 1.414 0.753 0.478 
2.694 (500ng/ml) 0.059 0.064 2.387 2.290 2.181 1.589 1.469 0.767 0.547 
2.347 (250ng/ml) 0.054 0.058 2.291 2.123 2.065 1.569 1.572 0.574 0.536 
1.408 (125ng/ml) 0.056 0.057 
C
ryopreserved 
E
ncapsulated P
orcine 
H
epatocyte 2.28 2.321 2.166 1.668 1.399 0.756 0.423 
0.756 (62.5ng/ml) 0.058 0.059 2.511 2.46 2.027 1.664 1.371  0.853 0.567 
0.552 (31.25ng/ml) 0.057 0.06 2.442 2.666 2.101 1.679 1.385  0.880 0.566 
0.382(15.625ng/ml) 0.073 0.061 2.516 2.730 2.197 1.664 1.487  0.875 0.565 
0.282 (7.8ng/ml) 0.06 0.069 
E
ncapsulated P
orcine 
H
epatocyte 2.525 2.785 2.141 1.646 1.374  0.879 0.575 
 
 
 
Standard Pig Reference Serum Albumin
y = 0.0051x + 0.4756
R2 = 0.8872
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X (concentration (ng/ml) = (Y (OD) – 0.4756) / 0.0051 
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  Day1 Day2 Day3 Day4 Day5 Day6 Day7 
Cryopreserved 
Encapsulated 
Porcine 
Hepatocyte 
2.2897 2.2490 2.1475 1.6072 1.4635 0.7125 0.4960 
Average of OD  
(Y) 
Encapsulated 
Porcine 
Hepatocyte 
2.4985 2.6602 2.1165 1.6632 1.4042 0.8717 0.5682 
Cryopreserved 
Encapsulated 
Porcine 
Hepatocyte 
355.706 347.725 327.824 221.882 193.706 46.451 4 
Concentration 
(ng/ml) (X) 
Encapsulated 
Porcine 
Hepatocyte 
396.647 428.353 321.745 232.863 182.078 77.667 18.157 
Cryopreserved 
Encapsulated 
Porcine 
Hepatocyte 
7114 6954 6556 4437 3874 929 80 
Final Actual 
Concentration 
(ng/ml) 
Sample 
Dilution 1:20 
Encapsulated 
Porcine 
Hepatocyte 
7932 8567 6434 4657 3641 1553 363 
 
6. In vivo studies 
Time after Tx 
No. of 
acute 
liver 
failure 
C57BL/6 
mouse 
Hours 
12 
Hours 
24 
Hours 
36 
Hours 
48 
Hours 
60 
Hours 
72 
Hours 
96 
Day 
5 
Day 
6 
Day 
7 
Day 
10 
Day 
14 
Survival 
rate 
Tx of fresh 
encapsulated 
porcine 
hepatocytes 
10 10 10 9 9 9 8 8 8 8 8 8 8 80% 
Tx of 
cryopreserved 
encapsulated 
porcine 
hepatocytes 
9 9 9 8 8 7 7 7 6 6 6 6 6 67% 
 
C.3rd time of porcine hepatocytes isolation 
1. Total hepatocytes after isolation and purification: 1469X 106 cells 
2. Pig liver: 134g 
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3. 10.96X 106 cells per gram of liver tissue 
4. Viability of isolated hepatocytes: 79% 
 
  
Cell Number  
(Chamber I) 
Cell number  
(Chamber II) 
%Viable 
(I)  
%Viable 
(II) 
c/mL*e6 (I) c/mL*e6 (II)  
Avg. 
Viable 
Avg. 
cells/mL*e6  
Dead 27 23   
Viable 101 84 79% 78.5 16 13.38 79% 14.69 
 
5. In vitro albumin secretion  
ELISA  
OD=Optical Density   
CM=Culture Medium 
Sample Dilution 1:20 
 
Standard Pig 
Reference Serum 
Albumin 
(OD=Optical 
Density) 
CM 
with 
FBS 
CM 
without 
FBS 
 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
 0.094 0.075 2.026 1.658 1.609 1.311 1.106 0.782 0.668 
2.852 (500ng/ml) 0.082 0.066 1.973 1.744 1.687 1.316 1.105 0.793 0.736 
2.377 (250ng/ml) 0.083 0.062 2.033 1.653 1.625 1.306 1.102 0.767 0.678 
1.623 (125ng/ml) 0.089 0.066 
P
rim
ary P
orcine 
H
epatocyte 1.942 1.646 1.602 1.304 1.109 0.795 0.717 
0.876 (62.5ng/ml) 0.085 0.067 2.213 1.674 1.522 1.636 1.174 1.123 0.705 
0.478(31.25ng/ml) 0.082 0.073 2.199 1.668 1.526 1.534 1.167 1.115 0.973 
0.248(15.625ng/ml) 0.088 0.072 2.225 1.695 1.534 1.552 1.153 1.107 0.923 
0.157 (7.8ng/ml) 0.092 0.073 
E
ncapsulated P
orcine 
H
epatocyte 2.311 1.666 1.528 1.518 1.161 1.118 0.959 
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Standard Pig Reference Serum Albumin
y = 0.0056x + 0.4376
R2 = 0.8722
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X (concentration (ng/ml) = (Y (OD) – 0.4376) / 0.0056 
 
  Day1 Day2 Day3 Day4 Day5 Day6 Day7 
Primary 
Porcine 
Hepatocyte 
1.9935 1.6725 1.6308 1.3092 1.1055 0.7842 0.6997 
Average of OD  
(Y) Encapsulated 
Porcine 
Hepatocyte 
2.2370 1.6757 1.5275 1.5600 1.1637 1.1157 0.8900 
Primary 
Porcine 
Hepatocyte 
277.839 220.518 213.071 155.623 119.268 61.893 46.804 
Concentration 
(ng/ml) (X) Encapsulated 
Porcine 
Hepatocyte 
321.321 221.089 194.625 200.429 129.661 121.089 80.786 
Primary 
Porcine 
Hepatocyte 
5556 4410 4261 3112 2385 1237 936 
Final Actual 
Concentration 
(ng/ml) 
Sample 
Dilution 1:20 
Encapsulated 
Porcine 
Hepatocyte 
6426 4421 3892 4008 2593 2421 1615 
 
6. In vivo studies 
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Time after Tx 
No. of 
acute 
liver 
failure 
C57BL/6 
mouse 
Hours 
12 
Hours 
24 
Hours 
36 
Hours 
48 
Hours 
60 
Hours 
72 
Hours 
96 
Day 
5 
Day 
6 
Day 
7 
Day 
10 
Day 
14 
Survival 
rate 
Tx of fresh 
encapsulated 
porcine 
hepatocytes 
10 10 10 10 9 9 8 8 8 8 8 8 8 80% 
Tx of 
cryopreserved 
encapsulated 
porcine 
hepatocytes 
10 10 10 9 9 9 7 7 6 6 6 6 6 60% 
 
D.4th time of porcine hepatocytes isolation 
1. Total hepatocytes after isolation and purification: 1400X 106 cells 
2. Pig liver: 167g 
3. 8.38 X 106 cells per gram of liver tissue 
4. Viability of isolated hepatocytes: 81.5% 
 
 
Cell Number  
(Chamber I) 
Cell number  
(Chamber II) 
%Viable 
(I) 
%Viable 
(II) 
c/mL*e6 (I) c/mL*e6 (II) 
Avg. 
Viable 
Avg. 
cells/mL*e6 
Dead 6 7  
Viable 28 29 82.4% 80.5% 17 18 81.5% 17.5 
 
5. In vitro albumin secretion  
ELISA  
OD=Optical Density   
CM=Culture Medium 
Sample Dilution 1:20 
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Standard Pig 
Reference Serum 
Albumin 
(OD=Optical 
Density) 
CM 
with 
FBS 
CM 
without 
FBS 
 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
 0.087 0.094 2.396 1.536  1.503 1.387 1.348 1.122 0.952 
2.702 (500ng/ml) 0.082 0.089 2.379 1.556  1.462 1.387 1.373 1.128 0.934 
2.347 (250ng/ml) 0.082 0.079 2.282 1.553  1.467 1.381 1.371 1.121 0.927 
1.617 (125ng/ml) 0.089 0.069 
C
ryopreserved 
E
ncapsulated P
orcine 
H
epatocyte 2.337 1.54  1.491 1.393 1.36 1.121 0.914 
0.906 (62.5ng/ml) 0.098 0.068 2.556 2.313 1.813  1.767 1.246 1.158 1.213 
0.499(31.25ng/ml) 0.093 0.067 2.526 2.355 1.866  1.752 1.258 1.168 1.226 
0.278(15.625ng/ml) 0.093 0.072 2.547 2.311 1.808  1.775 1.238 1.166 1.239 
0.181 (7.8ng/ml) 0.093 0.067 
E
ncapsulated P
orcine 
H
epatocyte 2.653 2.327 1.838  1.782 1.296 1.176 1.274 
 
 
 
Standard Pig Reference Serum Albumin
y = 0.0052x + 0.4765
R2 = 0.8506
0
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X (concentration (ng/ml) = (Y (OD) – 0.4765) / 0.0052 
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  Day1 Day2 Day3 Day4 Day5 Day6 Day7 
Cryopreserved 
Encapsulated 
Porcine 
Hepatocyte 
2.348 1.546 1.481 1.387 1.363 1.123 0.932 
Average of OD  
(Y) 
Encapsulated 
Porcine 
Hepatocyte 
2.571 2.327 1.831 1.769 1.260 1.167 1.238 
Cryopreserved 
Encapsulated 
Porcine 
Hepatocyte 
359.904 205.637 193.173 175.096 170.481 124.327 87.596 
Concentration 
(ng/ml) (X) 
Encapsulated 
Porcine 
Hepatocyte 
402.788 355.865 260.481 248.558 150.673 132.788 146.442 
Cryopreserved 
Encapsulated 
Porcine 
Hepatocyte 
7198 4113 3863 3501 3409 2486 1751 
Final Actual 
Concentration 
(ng/ml) 
Sample 
Dilution 1:20 
Encapsulated 
Porcine 
Hepatocyte 
8055 7117 5209 4971 3013 2655 2928 
 
6. In vivo studies 
Time after Tx 
No. of 
acute 
liver 
failure 
C57BL/6 
mouse 
Hours 
12 
Hours 
24 
Hours 
36 
Hours 
48 
Hours 
60 
Hours 
72 
Hours 
96 
Day 
5 
Day 
6 
Day 
7 
Day 
10 
Day 
14 
Survival 
rate 
Tx of fresh 
encapsulated 
porcine 
hepatocytes 
11 11 11 10 10 9 8 8 8 8 8 8 8 73% 
Tx of 
cryopreserved 
encapsulated 
porcine 
hepatocytes 
12 12 11 11 11 10 10 9 9 9 9 9 9 75% 
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E.  Survival rates of control groups 
Time after 
Tx 
No. of 
acute 
liver 
failure 
C57BL/6 
mouse 
Hours 
12 
Hours 
24 
Hours 
36 
Hours 
48 
Hours 
60 
Hours 
72 
Hours 
96 
Day 
5 
Day 
6 
Day 
7 
Day 
10 
Day 
14 
Survival 
rate 
Tx of empty 
capsules 
11 8 6 4 3 3 3 2 2 2 2 2 2 18% 
Tx of free 
primary 
porcine 
hepatocytes 
12 9 8 8 7 6 4 4 3 3 3 3 3 25% 
 
 
F.  Results in summary 
Viability 
Immediately after isolation, viability of porcine hepatocytes was 64%, 81%, 
79% and 81.5%, respectively. Viability of primary porcine hepatocytes was 76.3± 
8.3%.  
In vitro albumin secretion 
Freshly isolated or cryopreserved encapsulated porcine hepatocytes showed 
a similar continuous decrease of albumin secretion during the first week of culture 
similarly to free freshly isolated porcine hepatocytes, becoming almost undetectable 
at 7 days (Figure 1).  
In vivo studies 
FLF was achieved by combination of acetaminophen and 30% hepatectomy, 
resulting in a survival of about 20%. In Groups 1 and 2, survival remained 
unmodified (18% and 25% respectively), compared to untreated mice. In Groups 3 
and 4, Tx of freshly isolated or cryopreserved encapsulated porcine hepatocytes 
significantly increased survival rate to 75% and 68%, respectively (P<0.01). 
(Figure2). 
Histopathology 
Histopathological examination of transplanted porcine hepatocyte capsules 
showed fibrotic formation up to one-month post-Tx. (Figure 4H and 4I) 
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Histopathology of native liver tissue demonstrated massive hemorrhage and 
extensive hepatocytes necrosis at 15 hours after acetaminophen administration 
(Figure 5A). In contrast, surviving mice showed complete recovery of native liver 
tissue 2 weeks post-Tx (Figure 5B). 
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Discussion 
 
Liver allo-transplantation is considered to be the only effective therapy for 
severe hepatic disorders, such as fulminant liver failure (FLF). However, the 
technical complexity, the shortage of human organ donors and the severe 
complications after transplantation limit the number of liver allo-transplants and are 
responsible for the approximately 15% incidence of mortality among patients on 
waiting lists.  
Human allogeneic hepatocyte transplantations have also been performed to 
correct enzymatic deficiencies or acute liver failure (25). However, the procedure is 
still hazardous and requires immunosuppression.  
Among the new sources of tissues for transplantation, xenogeneic 
hepatocytes have been considered feasible, and offer unlimited availability of liver 
tissue (26, 27). Many investigators have attempted to develop encapsulation 
techniques to prevent immunological damage and facilitate function of hepatocyte 
(28-34). In most encapsulated cell therapy studies, the intraperitoneal cavity is used 
as the site of transplantation. Despite of the development of fibrosis around the 
encapsulated cells, encapsulated allogeneic hepatocytes demonstrated an excellent 
survival and metabolic function.  
From this experimental standpoint, we decided to investigate whether 
intraperitoneal transplantation of cultured encapsulated xenogeneic hepatocytes 
could improve the survival rate and liver dysfunction in a fulminant hepatic failure 
mouse model induced by a combination of acetaminophen administration and 30% 
hepatectomy. Therefore, we transplanted cultured microencapsulated porcine 
hepatocytes, which were thought to have a high level of hepatic function, into a 
fulminant hepatic failure model. 
In the present study, we tested the in vitro and in vivo function of isolated 
hepatocytes obtained from swine after encapsulation, cryopreservation (35). The in 
vitro experiments showed that primary porcine hepatocytes maintained synthetic 
functions after encapsulation and cryopreservation only short term. Freshly isolated 
free porcine hepatocytes showed a continuous decrease of albumin secretion within 
the first week of culture, becoming almost undetectable at 7 days. A decreasing 
albumin secretion was also observed for porcine hepatocytes, regardless if the cells 
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were encapsulated or cryopreserved, over one week in culture. This result is in 
accordance with several studies showing that free primary hepatocytes are difficult to 
maintain in culture (36-41). Interestingly, encapsulated porcine hepatocytes, fresh or 
cryopreserved, demonstrated a higher albumin secretion at one week of culture, 
compared to free primary hepatocytes (Figure 1). This result suggests that capsules 
represented a more appropriate environment for cell growth and maintenance of 
biological functions.   
To test the effect of these cells in vivo, we developed a new model of FLF in 
mice using a combination of acetaminophen administration and 30% hepatectomy. 
This model achieved a reproducible mortality of 80% in untreated mice (42).  
In vivo, after intraperitoneal Tx of empty capsules as control (Group 1), no 
improvement of survival was achieved. Intraperitoneal delivery of nonencapsulated 
fresh primary porcine hepatocytes (Group 2) did also not modify survival of mice with 
FLF, indicating a rapid loss of transplanted cells, possibly due to innate or humoral 
rejection mechanisms. 
In contrast, Tx of encapsulated fresh porcine hepatocytes (Group 3) 
significantly increased survival rate to mice with FLF from 20% to 75% (p<0.01), 
suggesting that encapsulation protects hepatocytes from recipient immune 
responses. 
Delivery of cryopreserved encapsulated cells (Group 4) similarly improved 
survival (increased survival rate to mice with FLF from 20% to 68% (p<0.01)), 
demonstrating that cryopreservation did not alter significantly hepatocyte function 
and indicating these cells still maintained some specific hepatocyte functions and 
were resistant to cryopreservation.  
In this study, >50×106 microencapsulated hepatocytes were transplanted into 
the abdominal cavity of FLF mice. The exact number of cells that should be 
transplanted in an acute hepatic failure model remains controversial. Many 
investigators have stated that a hepatocyte count of less than 5% of the original liver 
mass may be insufficient to complement the damaged liver mass (43). After one-day 
culture before transplantation, the encapsulated porcine hepatocytes demonstrated a 
high hepatic function that enabled the damaged liver to be supported immediately 
after transplantation. On the basis of this result, we believe that not only the number 
of cells but also the level of hepatic function is important for the support of severe 
liver damage. Nevertheless, the issue of the optimal cell number required to improve 
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a patient’s fulminant hepatic failure status needs to be further studied for future 
clinical applications. 
These first results demonstrate that encapsulated primary xenogeneic porcine 
hepatocytes (cryopreserved or non- cryopreserved) can maintain metabolic functions 
for a short period of time to bridge FLF and allow regeneration of native liver tissue. 
Histopathology of liver tissue showed massive hemorrhage and extensive 
hepatocytes necrosis at 15 hours after acetaminophen administration. In contrast, 
surviving mice showed complete recovery of liver tissue after 2 weeks (Figure 5). 
Encapsulated cells survived and fibrosis around the capsule wall was minimal, even 
though the capsule itself was a foreign body. 
We showed that the intraperitoneally transplantation of cultured 
microencapsulated hepatocytes (cryopreserved or non- cryopreserved) enabled 
mice with fulminant hepatic failure to survive. The encapsulated hepatocytes were 
well preserved and strongly expressed albumin, a marker of hepatic function, with 
minimum fibrotic reactions around the capsule wall. Therefore, the hepatocytes 
inside the alginate capsules appeared to be capable of supporting the hepatic 
function of the damaged liver without the need for immunosuppression, allowing the 
native liver time to regenerate.  
In summary, the data presented in this study indicate that xenogeneic porcine 
hepatocytes can be isolated, encapsulated, cryopreserved and still maintain 
biological functions in vitro. When transplanted intraperitoneally into mice with FLF, 
encapsulated xenogeneic porcine hepatocytes provided life-supporting liver-specific 
metabolic functions requiring no immunosuppressive therapy. These findings have 
great potential for clinical use, as encapsulated xenogeneic could be easily stored as 
described here and injected intraperitoneally in patients with FLF. However, prior to 
initiate any clinical trial, these results must be tested in large animal models of FLF. 
The mouse model we have developed combined a toxic and a traumatic injury of the 
liver. As in most animal models, the physiopathology does not reflect completely the 
various clinical situations. Therefore, the effect of hepatocyte transplantation could 
certainly not have the same effect in humans with acute liver failure. We plan to 
repeat these experiments in a large animal model, i.e. we will use a porcine model of 
acute liver failure induced by liver ischemia.   
   
Jie MEI                                                                                                             2006 63 
In conclusion, the intraperitoneal transplantation of cultured 
microencapsulated porcine hepatocytes allowed a fulminant hepatic failure mouse 
model, induced by a combination of acetaminophen administration and 30% 
hepatectomy, to survive without the need for immunosuppression. These results 
indicate that encapsulated naïve xenogeneic porcine hepatocytes can be 
successfully stored using cryopreservation, display liver metabolic functions to 
support damaged liver function, and enable the native liver to vigorously regenerate. 
This novel technique is likely to provide a new direction in encapsulated cell therapy 
toward clinical applications in the near future. 
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Figures legends 
Figure 1 
Fresh or cryopreserved encapsulated porcine hepatocytes showed a similar 
continuous decrease of albumin secretion during the first week of culture similarly to 
free freshly isolated porcine hepatocytes, becoming almost undetectable at 7 days.  
Figure 2 
In Group 1 (N=11, Tx of empty capsules) and Group 2 (N=12, Tx of free primary 
porcine hepatocytes) survival was 18% and 25% respectively. In Group 3 (N=36, Tx 
of encapsulated fresh porcine hepatocytes) and Group 4 (N=38, Tx of encapsulated 
cryopreserved porcine hepatocytes) survival rate was significantly increased to 75% 
and 68%, respectively (P<0.01).  
Figure 3 
Figure 3A: Fresh isolated porcine hepatocytes. 
Figure 3B: Primary culture of porcine hepatocytes at day 1, x25. 
Figure 3C: Primary culture of porcine hepatocytes at day 3, x100. 
Figure 3D: Primary culture of porcine hepatocytes at day 5, x100. 
Figure 4 
Figure 4A and 4B: Encapsulation of porcine hepatocytes. 
Figure 4C: Empty capsules. 
Figure 4D: Cultured encapsulated porcine hepatocytes at day 1, x100. 
Figure 4E: Cultured encapsulated porcine hepatocytes at day 3, x100. 
Figure 4F and 4G: Histopathological examination of transplanted empty capsules 
showed fibrotic formation up to one-month post-Tx. (Haematoxylin-Eosin x100, 
x200). 
Figure 4H and 4I: Histopathological examination of transplanted porcine hepatocyte 
capsules showed fibrotic formation up to one-month post-Tx. (Haematoxylin-Eosin 
x100, x200). 
Figure 5 
Figure 5A: Massive hemorrhage of mouse liver at 15 hours after acetaminophen 
administration.  
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Figure 5B and 5C: Histopathology of native liver tissue demonstrated massive 
hemorrhage and extensive hepatocytes necrosis at 15 hours after acetaminophen 
administration (Haematoxylin-Eosin x100, x200).  
Figure 5D and 5E: In contrast, surviving mice showed complete recovery of native 
liver tissue 2 weeks post-transplantation (Haematoxylin-Eosin x100, x200). 
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Figures 
Figures 1:  In vitro test of albumin secretion 
Primary Porcine Hepatocytes: 
Concentration 
(ng/ml) 
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
1st 6252 5531 5125 4612 3648 1568 723 
3rd 5556 4410 4261 3112 2385 1237 936 
Average 5904 4970.5 4693 3862 3016.5 1402.5 829.5 
SD 492.1463 792.6667 610.9403 1060.66 893.0759 234.0523 150.6137 
 
Encapsulated Porcine Hepatocytes: 
Concentration 
(ng/ml) 
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
1st 8348 8432 8630 7899 5207 771 149 
2nd 7932 8567 6434 4657 3641 1553 363 
3rd 6426 4421 3892 4008 2593 2421 1615 
4th 8055 7117 5209 4971 3013 2655 2928 
Average 7690.25 7134.25 6041.25 5383.75 3613.5 1850 1263.75 
SD 860.7068 1923.447 2013.934 1724.113 1146.301 861.4941 1284.15 
 
Cryopreserved Encapsulated Porcine Hepatocytes: 
Concentration 
(ng/ml) 
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
2nd 7114 6954 6556 4437 3874 929 80 
4th 7198 4113 3863 3501 3409 2486 1751 
Average 7156 5533.5 5209.5 3969 3641.5 1707.5 915.5 
SD 59.39697 2008.89 1904.239 661.8519 328.8047 1100.965 1181.575 
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Figures 2:  In vivo study 
Survival rate 
Time after Tx 
No. of 
acute 
liver 
failure 
C57BL/6 
mouse 
Hours 
12 
Hours 
24 
Hours 
36 
Hours 
48 
Hours 
60 
Hours 
72 
Hours 
96 
Day 
5 
Day 
6 
Day 
7 
Day 
10 
Day 
14 
Survival 
rate 
Group 1  
Tx of empty 
capsules 
11 8 6 4 3 3 3 2 2 2 2 2 2 18% 
Group 2  
Tx of free 
primary 
porcine 
hepatocytes 
12 9 8 8 7 6 4 4 3 3 3 3 3 25% 
Group 3  
Tx of fresh 
encapsulated 
porcine 
hepatocytes 
36 36 36 33 32 30 27 27 27 27 27 27 27 75% 
Group 4  
Tx of 
cryopreserved 
encapsulated 
porcine 
hepatocytes 
38 38 36 34 33 31 29 28 26 26 26 26 26 68% 
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PH = porcine hepatocyte 
Group 1 vs Group 2  P=0.42467 
Group 1 vs Group 3  P=0.0001 
Group 1 vs Group 4  P=0.00035 
Group 3 vs Group 4  P=0.58391 
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